A high degree of homology between the four G s -coupled prostaglandin (PG) receptors [EP 2 , EP 4 , prostacyclin (IP), PGD 2 (DP)] and the four G q /G i -coupled receptors [EP 1 , EP 3 , PGF 2␣ (FP), thromboxane A 2 (TP)] suggests that prostaglandin receptors evolved functionally from an ancestral EP receptor before the development of distinct binding epitopes. If so, ligand selectivity should be determined by a limited number of amino acids. EP 2 receptor transmembrane domain residues that are similar to those in the EP 4 receptor but differ from those in the IP receptor were mutated to the corresponding IP receptor residue. Activation of the mutant receptors by PGE 2 (EP 2 ligand), iloprost (stable prostacyclin analog), and PGE 1 (EP 2 /IP ligand) was determined using a cAMP-dependent reporter gene assay. A Leu304-to-tyrosine substitution in the seventh transmembrane domain enhanced iloprost potency approximately 100-fold. A glycine substitution at Ser120 in the third transmembrane domain had no effect on drug potency but improved the response of the Tyr304 mutant. The potency of the natural prostaglandins PGF 2␣ and PGD 2 was not enhanced by the mutations. In contrast, the potency of all prostaglandins was reduced 10-to 100-fold when arginine 302, which is thought to be a counterion for the prostaglandin carboxylic acid, was mutated. Thus, a single amino acid change resulted in a selective gain of function for iloprost, which is consistent with the proposed phylogeny of the prostaglandin receptors.
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The molecular identification of eight G protein-coupled membrane receptors that mediate the actions of the five primary prostaglandins has helped to explain the myriad of biological effects of these arachidonic acid metabolites. In particular, PGE 2 affects almost every tissue in the body (often in opposing ways), including smooth muscle contraction and relaxation and pro-inflammatory and anti-inflammatory actions. Four subtypes of the PGE 2 receptor, termed EP 1 , EP 2 , EP 3 , and EP 4 , have been cloned (Pierce et al., 1995) and shown to couple to different signaling systems. The EP 1 receptor couples preferentially to G q , the EP 2 and EP 4 receptors couple to G s , and the six EP 3 receptor carboxyl tail splice variants couple to G i . Thus, these four receptors respond quite differently to the same physiological ligand.
Surprisingly, when the deduced amino acid sequences for the four EP receptors are aligned and compared, they demonstrate an unexpected degree of divergence. Alignments of all the prostaglandin receptors showed that the EP 2 receptor is more similar to the IP receptor and the DP receptor than to the other three EP receptors. Phylogenetic analysis (Regan et al., 1994; Toh et al., 1995) of receptor sequences led to the conclusion that the prostaglandin receptors evolved from a precursor EP receptor into two subfamilies that differ with respect to their G protein coupling (Fig. 1A) . Receptors that preferentially interact with the major endogenous prostaglandins other than PGE 2 must have evolved following the functional division of the EP receptors. Thus, the IP and DP receptors evolved from the EP 2 receptor, and the FP and TP receptors evolved from the EP 3 or EP 1 receptor. If this hypothesis is correct, a relatively small number of amino acids may determine the selective interactions of the prostaglandins with their receptors.
The EP 2 and the IP receptors represent an ideal receptor pair for studying the determinants of ligand selectivity. Their seven TMs are more than 60% identical at the amino acid level and they share some common ligands, such as PGE 1 . However, PGE 2 is more than 1000-fold selective for the EP 2 receptor, and the stable prostacyclin analog iloprost is more than 1000-fold selective for the IP receptor. We identified approximately 15 residues that were similar in the EP 2 and EP 4 receptor but differed in the IP receptor. To determine whether these amino acid residues were responsible for the preferential activities of PGE 2 and iloprost, the EP 2 receptor sequence was changed at these positions to the correspond-ing IP receptor amino acid (Fig. 1B) by site-directed mutagenesis and the effect on activation by PGE 2 and iloprost determined in a reporter gene assay. PGE 1 , a ligand at both the EP 2 and IP receptors, was used to confirm that the mutant receptors were functionally expressed.
A single amino acid change in TM7 enables iloprost to activate the EP 2 receptor. This mutant receptor is activated by both PGE 2 and iloprost, but not by PGD 2 or PGF 2␣ . This represents the first report of a single amino acid change in a prostaglandin receptor resulting in a gain of function for prostaglandin ligands and is consistent with the proposed phylogeny of the prostaglandin receptors. Fig. 1 . Phylogeny of human prostaglandin receptors. A, Alignment of deduced amino acid sequences of eight cloned human prostaglandin receptors was used to generate the phylogenetic tree (Regan et al. 1994) . Site-directed mutagenesis. Missense mutations were introduced by the Kunkel method (Kunkel, 1985) using a Muta-Gene kit purchased from BioRad (Richmond, CA). The human EP 2 receptor cDNA (Regan et al., 1994) was placed in pcDNA3 (InVitrogen, Carlsbad, CA) for all mutagenesis and expression studies. Oligonucleotides were purchased from Genosys (The Woodlands, TX) or synthesized in-house on an Oligo1000 oligonucleotide synthesizer (Beckman Instruments, Fullerton, CA). Mutations were verified by DNA sequence analysis using a Sequenase kit (Amersham Life Sciences, Arlington Heights, IL). The double mutant EP 2 S120G L304Y was constructed from two single mutants by using the internal ApaI restriction site and standard protocols.
Expression of EP 2 cDNAs in cell culture. CV-1 cells were transiently transfected with plasmids carrying the wild-type or mutant EP 2 cDNA using lipofectamine. The CRE-CAT reporter plasmid TESblgIICRE(ϩ)⌬NHSE was obtained from Dr. Pamela Mellon of The Salk Institute (La Jolla, CA). This construct contains an 18-base-pair CRE from the promoter of the ␣ subunit gene for the human glycoprotein hormone linked to the herpes simplex virus thymidine kinase promoter, which drives bacterial CAT gene expression (Delegeane et al., 1987) . Thus, CAT enzyme activity is dependent on and proportional to cAMP levels in the cells. Fifty thousand cells were plated in wells of a 24-well plate and transfected with 125 ng of receptor plasmid, 250 ng of reporter plasmid, and 6 g of lipofectamine per well. Cells were fed with Dulbecco's modified Eagle's medium containing 20% stripped fetal bovine serum at approximately 5 hr. Cells were dosed with drug approximately 24 hr after feeding, and assayed for CAT activity approximately 18 hr after dosing.
CAT assay. Medium was removed by aspiration and the cells washed twice with ice-cold phosphate-buffered saline (1ϫ ϭ 0.02% KCl, 0.02% KH 2 PO 4 , 0.8% NaCl, 0.216% Na 2 HPO 4 ⅐7H 2 O) without calcium or magnesium. Lysis buffer (50 l) containing 1% Triton X-100, 1 mM Tris⅐HCl, pH 7.8, and 2 mM EDTA, pH 8.0, and 0.4 mg/ml DNase I was added and cells lysed on ice with periodic shaking for 45 min. Reaction mix (50 l) containing 40 M [ 3 H]acetyl coenzyme A, 60 M acetyl coenzyme A, 30 M HCl, 2 mM chloramphenicol, 200 mM Tris⅐HCl, pH 7.8, and 4 mM EDTA, pH 8.0, was added to the lysate and the mixture incubated for 90 min at 37°. The reaction was stopped with 100 l of 7 M urea and the entire volume (200 l) transferred to scintillation vials. One milliliter of scintillant (0.8% 2,5-diphenyloxazole in toluene) was added and the vials shaken to mix the phases. The phases were allowed to separate for 15 min before reading in a scintillation counter, to allow the [ 3 H]acetylated chloramphenicol product to partition into the nonpolar phase (Nielsen et al., 1989) . Samples were assayed in triplicate and average dpm values were obtained.
Data analysis. Because PGE 1 is the common ligand for EP 2 and IP receptors, all values were expressed as a percentage of the maximum PGE 1 value. The basal value for each dose-response curve was subtracted from all dpm values. The highest PGE 1 value for each receptor on each assay day was considered 100%. Dose-response curves were generated using KaleidaGraph (Abelbeck/Synergy Software, Reading, PA) by least-squares fits to this equation: response ϭ maximum response ϩ (minimum response Ϫ maximum response)/[1 ϩ (concentration of ligand/EC 50 )]. The data are reported as mean Ϯ standard error of three to 12 independent experiments.
Results
To identify key residues for ligand discrimination, mutants were screened for CAT activity in a CRE-CAT reporter gene assay, using 0.1, 10, and 100 nM concentrations of PGE 1 , PGE 2 , and iloprost (data not shown). Because PGE 1 activity should not be affected by mutations that alter ligand selectivity between the EP 2 and IP receptors, it was used to assess the functionality of the mutant receptors. Mutants that were not activated by PGE 1 were assumed to be inappropriately expressed or improperly assembled and were not pursued further. The majority of mutants were unremarkable, in that they retained the ability to signal in response to PGE 1 and PGE 2 and did not gain the ability to signal in response to iloprost (Table 1) . Active mutants were assayed for CAT activity over a complete range of doses from 1 nM to 10 M.
EP 2 activity. The EP 2 receptor demonstrated function, as determined by CAT activity, in response to PGE 1 and PGE 2 ( Fig. 2A) . EC 50 values of 34.0 Ϯ 11.0 nM for PGE 1 and 25.5 Ϯ 6.6 nM for PGE 2 are in the range of previously published values for the EP 2 receptor (Regan et al., 1994; Nishigaki et al., 1996) . The EP 2 receptor responds to iloprost ( Fig. 2A) , carbacyclin (Fig. 3) , PGD 2 , and PGF 2␣ (Fig. 2E) only at micromolar concentrations, as previously reported.
Residue 304 is a key determinant of selective ligand interaction. The mutant receptor EP 2 L304Y was activated in response to PGE 1 , PGE 2 , and iloprost (Fig. 2B) . The EC 50 values are 99.9 Ϯ 29.5 nM for PGE 1 , 33.3 Ϯ 11.2 nM for PGE 2 , and 128.9 Ϯ 38.3 nM for iloprost. The potency of iloprost is increased at least 50-fold because of the mutation at position 304.
Computer modeling (data not shown) suggested that residue 120 in TM3 participates in interactions with residue 304 in TM7. For this reason, mutant EP 2 S120G and the double mutant EP 2 S120G L304Y were generated and analyzed. Mutant EP 2 S120G retains the ability to respond to PGE 1 and PGE 2 (EC 50 values of 47.4 Ϯ 21.1 nM and 33.0 Ϯ 11.7 nM, respectively) without responding to iloprost except at micromolar concentrations (Fig. 2C) . It seems to respond much as (Fig. 2D) . It retains the ability to signal in response to PGE 1 and PGE 2 (EC 50 values of 36.0 Ϯ 10.0 nM and 37.9 Ϯ 12.3 nM, respectively), and has gained the ability to respond to iloprost (EC 50 of 142.1 Ϯ 43.4 nM) and carbacyclin ( Fig. 3 ; EC 50 of 1705.0 Ϯ 734.1 nM). No response to PGD 2 or PGF 2␣ is seen at submicromolar concentrations (Fig. 2F) . Interestingly, the overall signal magnitude, as a percent of basal, of the double mutant EP 2 S120G L304Y is consistently superior to that of the single mutant EP 2 L304Y, suggesting that residue 120 in TM3 interacts in some way with residue 304, perhaps by stabilizing the receptor (Fig. 4) .
Arginine 302 is a key residue for prostaglandin activity. The conserved arginine residue in TM7 has been proposed to be the counterion for binding of the carboxyl group of prostaglandin compounds. Previous studies have demonstrated that alterations of this residue in EP 3 and TP prostaglandin receptors alters ligand binding and signaling (Funk et al., 1993; Huang and Tai, 1995; Negishi et al., 1995; Audoly and Breyer, 1997; Chang et al., 1997) . To confirm the significance of this residue in receptor-ligand interactions for the G s -coupled branch of the prostaglandin receptor family, this arginine has been substituted with a neutral residue (R302Q) and a negatively charged residue (R302E) to evaluate the change in function of these mutants.
Both mutants, EP 2 R302Q and EP 2 R302E (Fig. 5, A 
Discussion
The proposed prostaglandin receptor phylogeny (Regan et al. 1994; Toh et al. 1995) led us to hypothesize that only a few amino acids determine the selective interactions of the prostaglandins with their receptors. The approximately 100-fold increase in the activity of an IP receptor-selective agonist with a single amino-acid substitution confirms this hypothesis and is consistent with the proposed phylogeny.
The phylogenetic analysis highlighted candidate amino acids for gain of function mutations that could be rapidly screened with our functional assay (Fig. 1B) . This approach avoided the difficulties of interpreting loss of functional or binding activity, which can result from defective receptor synthesis and assembly rather than a change in ligand-receptor interactions. Only one recent study that swapped regions of the IP and DP receptors identified a gain of function, although this was not specific for a single type of prostaglandin (Kobayashi et al., 1997) . A nonspecific enhancement of activity could result from a general change in the activation kinetics of the receptors.
The role of residue 304 in ligand activation is specific to prostacyclin receptor agonists. The EP 2 L304Y and EP 2 S120G L304Y mutants acquire the ability to respond to the IP ligand iloprost, but not to the DP ligand PGD 2 or the FP ligand PGF 2␣ (Fig. 2F) . Thus, the specific gain of function seen in the EP 2 L304Y and EP 2 S120G L304Y mutants is Comparison of signal magnitude of the EP 2 L304Y and EP 2 S120G L304Y mutant receptors. Points, mean Ϯ standard error of four experiments with triplicate determinations, performed on cells transfected in the same experiment with the two mutant cDNAs. The basal activity was approximately 25,000 dpm for EP 2 L304Y and 10,000 dpm for EP 2 S120G L304Y, with the average increase over basal for iloprost of 2.6-fold and 3.6-fold, respectively. likely caused by an alteration in the vicinity of TM7, at a site that specifically interacts with iloprost.
It seems likely that residue 304 is sensitive to structural alteration of the ␣ side chain. Prostacyclin and its stable analog, iloprost, have a constrained configuration because of an additional ring that is not present in PGE 2 . PGE 1 , which activates both EP 2 and IP receptors, has a much more flexible ␣ chain and presumably can adopt a configuration that enables interaction with either receptor. The iloprost chain, which differs from prostacyclin and PGE 2 , does not seem to interact with residue 304 because carbacyclin, another prostacyclin analog that has an chain identical to prostacyclin and PGE 2 and a constrained ␣ chain, also gains function with the EP 2 S120G L304Y mutant (Fig. 3) . It is interesting to note that the potency of carbacyclin relative to iloprost for the mutant is similar to its relative potency in binding to the IP receptor (Boie et al., 1994) . The data are thus consistent with the L304Y substitution's enhancing the ability of the prostacyclin ␣ chain to interact with the EP 2 receptor. One explanation for the result is that the hydroxyl moiety of tyrosine provides a new contact point for prostacyclin and its analogs, compensating for one that prostaglandins with a less constrained ␣ side chain possess.
Other contact points are necessary for the discrimination of prostaglandin ligands. The iloprost potency at the IP receptor is approximately 100-fold greater than its potency at EP 2 L304Y. There must also be amino acids responsible for reducing the potency of PGE 2 at the IP and other non-EP receptors. The region of the binding pocket that enables the selective interactions of PGE 2 , as well as PGD 2 and PGF 2␣ , may be distinct from TM7 and is likely involved in interactions with the cyclopentane ring. A recent study with chimeric IP/DP receptor constructs suggested a role for TM3 of the DP receptor in cyclopentane ring interactions (Kobayashi et al., 1997) . These authors also suggested that TM6 or TM7 is responsible for ␣ chain recognition, which is consistent with our results. In another study, mutagenesis of a conserved hydroxy amino acid in TM6 of the EP 3 receptor seemed to alter the selectivity of that receptor (Negishi et al., 1995) . The approach we used here can be applied to other receptor pairs (the EP 2 and DP receptors for instance) to identify significant determinants of cyclopentane ring interactions. A comparison of EP 2 and EP 4 receptors might also determine why PGE 2 is approximately 10-fold less potent at the EP 2 receptor than at other EP receptors.
Residue 120 in TM3 probably influences ligand activity by interacting with residue 304. The EP 2 S120G mutation alone has wild-type pharmacology, which indicates that this residue is not involved in defining a ligand interaction site (Fig.  2C) . However, EP 2 L304Y exhibits a loss of signal magnitude that is rescued by the double mutant, EP 2 S120G L304Y, which indicates that the TM3-TM7 interactions are important for optimal receptor function (Fig. 4) . The elevated basal activity of the single mutants may reflect reduced stability of the receptor in the inactive state, which is stabilized by G protein coupling or the double mutant. Further evidence that these two amino acids interact is the fact that the changes at these positions between EP 2 and IP receptors are complementary in side chain length and polarity.
Arg302, which is located in TM7 and corresponds with arginine residues that have been implicated in binding of the prostaglandin carboxylic acid moiety, is predicted on the basis of modeling to be situated at the opposite end of the binding pocket from TM3 and TM6. As expected for an amino acid that is conserved in all prostaglandin receptors, mutagenesis of this residue resulted in a nonselective reduction of agonist activity (Fig. 5) . The retention of signal transduction, however minor, with the Arg302 mutants EP 2 R302Q and EP 2 R302E is intriguing. The result is consistent with PG ligands having many receptor contact points, as previously discussed. Mutagenesis of the corresponding residue in other prostaglandin receptors has resulted in a range of responses from total loss of binding or signaling to retention of some signaling. In some studies (Funk et al., 1993; Huang and Tai, 1995) binding alone was evaluated, which may underestimate any residual function present in the TP and EP 3 mutants. In one case, functional studies using the synthetic EP 3 analog sulprostone supplemented binding studies and demonstrated that mutation of the conserved arginine in the EP 3 receptor resulted in complete loss of function (Audoly and Breyer, 1997) . However, other studies have demonstrated retention of some EP 3 function when PGE 2 but not sulprostone is the agonist (Negishi et al., 1995; Chang et al., 1997) .
There are only a few previous examples of a single amino acid change altering the selectivity of a receptor for endogenous ligands. In the somatostatin receptor subtype 5, substitution of Phe265 in TM6 with tyrosine increased the affinity of the 14-amino-acid form of somatostatin, so that it was comparable with its affinity for somatostatin receptor subtypes 1-4 (Ozenberger and Hadcock, 1995) . Mutation of Tyr129 in TM2 of endothelin receptor A to histidine, the corresponding amino acid in endothelin receptor B, enhanced endothelin-3 binding so that its affinity was similar to that of endothelin receptor B (Krystek et al., 1994; Lee et al., 1994) . These receptors, as well as the EP 2 , should support study of the evolution of ligand-receptor pairs. One would predict that the emergence of the particular amino acid changes that are described and novel endogenous ligands occurred at similar stages of evolution.
In summary, a single residue in TM7 of the EP 2 receptor that is changed in the IP receptor determines the activity of stable prostacyclin analogs. This result is consistent with a model of prostaglandins interacting with their receptors at a Fig. 5 . Activation of EP 2 R302Q and EP 2 R302E mutant receptors. Receptors were expressed in CV-1 cells and assayed by the CRE-CAT assay. Drugs used were PGE 1 (F), PGE 2 (f), and iloprost (OE). Points, mean Ϯ standard error of four experiments performed with triplicate determinations. A, The EP 2 R302Q mutant has EC 50 values of 1123.2 Ϯ 346.5 nM for PGE 1 and 238.3 Ϯ 53.8 nM for PGE 2 . Iloprost was not active. The basal activity was approximately 5000 dpm, with a 2.7 Ϯ 0.5-fold increase in the PGE 2 signal. B, The EP 2 R302E mutant has EC 50 values of 694.3 Ϯ 210.8 nM for PGE 1 and 949.8 Ϯ 297.2 nM for PGE 2 . Iloprost was not active. The basal activity was approximately 5000 dpm, with a 2.5 Ϯ 0.4-fold increase in the PGE 2 signal.
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at ASPET Journals on June 23, 2017 molpharm.aspetjournals.org universal contact point (TM7 arginine) and at other residues, probably in a pocket formed by TM7, TM6, and TM3 that enables ligand discrimination. The significant role of a single amino acid in the selectivity of the EP 2 receptor is consistent with the hypothesis that the IP receptor evolved from the EP 2 receptor. In effect, the mutant receptor represents a molecular "missing link" in the evolution of the IP receptor from the EP 2 receptor.
